Search

everythinglearnresearchcommunity

for

Search:↓

The user is experiencing hair thinning and shedding despite no family history of male pattern baldness. They are considering starting treatments like Minoxidil or finasteride.

A user started taking 1mg of finasteride daily but experienced anxiety and brain fog, considering reducing the dose to 0.5mg to adjust. They seek advice on whether this change could help manage side effects and hair shedding.

There are no tests to determine genetic follicle sensitivity for hair loss, and conclusions are based on hypothetical or post-balding observations. Finasteride is mentioned as an easy, consistent treatment option compared to natural treatments.

RU58841 showed promise for treating androgenic alopecia but research was halted due to financial and organizational changes. There were no significant safety concerns reported in human trials.

A user with high pre-finasteride estrogen levels is asking if they need to normalize their hormone levels before starting finasteride and whether they should postpone dermarolling until they begin finasteride. The user is 21.5 years old.

Hair loss treatments discussed include Minoxidil, Finasteride, and RU58841. HMI-115, a monoclonal antibody drug, is in phase 1 and 2 trials for different conditions, but its availability on the gray market is unlikely due to high production costs.

Dutasteride at 2.5mg is considered a potential hair loss cure due to its DHT-blocking ability, but there are concerns about side effects and individual responses. Minoxidil, finasteride, and RU58841 are also discussed, with mixed opinions on their effectiveness and safety.

The conversation discusses the use of RU58841, a non-FDA approved research chemical for hair loss, with mixed opinions on its safety and effectiveness. Some users are willing to try it as a last resort after other treatments like Minoxidil and Finasteride failed, while others express concerns about potential long-term side effects and lack of official research.

Results for Amplifica's AMP-303 hair loss treatment study are expected late summer 2024. The study, fully enrolled in Q1 2024, focuses on safety and tolerability.

A peptide-based delivery system for finasteride shows promise in reducing systemic side effects while maintaining hair growth effectiveness. Combining this with other treatments like minoxidil and RU58841 could enhance results with lower systemic absorption.